about
The effects of antihypertensive therapy on haemostatic parametersStatin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular diseaseAtorvastatin for diabetic macular edema in patients with diabetes mellitus and elevated serum cholesterol.The role of serum magnesium and calcium on the association between adiponectin levels and all-cause mortality in end-stage renal disease patients.Effects of 12 months treatment with L-selenomethionine on serum anti-TPO Levels in Patients with Hashimoto's thyroiditis.Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study.Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT studyRegression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment.Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.Losartan affects glomerular AKT and mTOR phosphorylation in an experimental model of type 1 diabetic nephropathy.Kidney function and estimated vascular risk in patients with primary dyslipidemiaThe estrogenic burden on vascular risk in male-to-female transsexuals.Lipid lowering drugs and gallstones: a therapeutic option?Liver enzymes: potential cardiovascular risk markers?Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study.Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population.Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis?The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma.Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis.Low molecular weight heparin (nadroparine) versus oral anticoagulant (acenocoumarol) in the long-term treatment of deep venous thrombosis: comparison of efficacy, safety and hospitalisation period in 105 patients.Serum homocysteine concentration as a marker of nutritional status of healthy subjects in Crete, Greece.Diet, serum homocysteine levels and ischaemic heart disease in a Mediterranean population.Overweight and obesity in Greek warship personnel: prevalence and correlations.Bone marrow microvascular density and angiogenic growth factors in multiple myeloma.The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions.Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort.Obesity-associated disorders before and after weight reduction by vertical banded gastroplasty in morbidly vs super obese individuals.Acute rhabdomyolysis caused by Spirulina (Arthrospira platensis).The hypolipidaemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population: a prospective study.Prevalence of metabolic syndrome according to different definitions in a hypertensive population.Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis.Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women.Hyperhomocysteinemia in Greek patients with inflammatory bowel disease.Predicting coronary heart disease risk using the Framingham and PROCAM equations in dyslipidaemic patients without overt vascular disease.Correlation of diabetic retinopathy and corneal neuropathy using confocal microscopy.Prevalence of vascular disease in metabolic syndrome using three proposed definitions.Impairment of anorectal function in diabetes mellitus parallels duration of diseaseComment on: effect of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemiaAcute cholestatic hepatitis caused by Teucrium polium L
P50
Q28165578-F8BC9940-A609-47CD-A373-E0BC7FE4CE97Q28369047-D6157D26-8415-420D-9316-A3FAA53A787DQ33589005-194DDD5E-A895-4D82-9F68-53E7065ABBF7Q34533678-E865B346-E0F6-43FA-8D77-6ECF7F3F8B1CQ34662735-70C92C41-5C25-4684-A222-77F3E56B7388Q35638342-0F1CB99B-03F2-425F-9EF2-AF30C137E17DQ35674320-9BFED95B-8AB5-4019-950A-3D2552F4EA5FQ36754160-22C9579A-5150-4B12-8112-8A12711A36FEQ36755797-35186CA4-A4A0-4D99-9961-13044BA2C478Q37024574-0325CB4F-F1DF-43EE-A986-C49D79BE3BC7Q37245464-C9CBAA7A-F1B7-4745-B721-6BF781112E87Q37815517-7D8D56E3-11BC-4E6C-992C-BEC75FD22433Q37954741-2212B243-8DD1-40F1-B889-E3223523F54BQ37954742-D435275A-A7DF-414C-B3E7-33DA6137BC68Q39702444-22E92E98-2F0F-4CB3-AB2C-DEB09E99618DQ39995819-ECDC48D1-B152-4D16-BEEC-55F4DA28B436Q43193058-508BB346-E1C6-41C5-BBCE-695F8F204B2CQ43821883-9300BDE6-3FD4-4FC5-9494-58217286CE82Q43977482-8096B8D0-9D58-4608-B589-E86E21812692Q44114292-1565F135-6234-4729-99AD-C495CB20020FQ44640242-24E3F108-4224-4913-8E66-78FFACFDFD1DQ44718854-BD41DBE9-A70B-43D4-B5A8-2B77BA9FFE5BQ44925406-34ACB2B5-F8B3-4354-B6D9-F6855AB1E611Q45150142-00DC203C-64EF-4FCE-95B6-246211FF2F15Q45155418-CE2C237B-D645-4432-A70A-1CCFDE039D12Q46637307-2DF38ED3-1966-413B-AFF5-D6D3DC8309E0Q46793872-62B786A6-AC89-4152-BCEE-DEFC83E29DE8Q47204503-58F5580B-9DEC-45BF-8C1E-76630911D9C0Q50459446-C9FA2DE8-FAF5-4F76-9AC1-DC74EA23A884Q50919319-9BAED8DE-A449-4D97-A8EA-AEBBD11A46E6Q51034935-329577D1-9D48-44BB-85C6-D266AE07E0C5Q51366717-00E7B0AD-9EA6-4CB3-829E-B32E305502E0Q51375175-DC9ADEC4-6A8F-4AF2-9716-BE88154F240CQ51550255-B724EE81-9550-4FC5-8C38-488548B68840Q51905705-B8686ABD-F631-4028-B5AC-A4E04A694351Q53159863-E648F6DF-F08D-424E-89F4-436B19B495A4Q53252633-62BC8113-324A-47E9-A85E-54E809BD4BD7Q73193993-B5386E77-EC72-487F-8BEE-618DD8FD7C55Q73284570-0415F273-C19B-4A52-A7E6-7C1F9B538720Q76365033-DAFA9E34-9793-4965-8C56-F0096CF2AE48
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Emmanuel Ganotakis
@ast
Emmanuel Ganotakis
@en
Emmanuel Ganotakis
@es
Emmanuel Ganotakis
@nl
Emmanuel Ganotakis
@sl
type
label
Emmanuel Ganotakis
@ast
Emmanuel Ganotakis
@en
Emmanuel Ganotakis
@es
Emmanuel Ganotakis
@nl
Emmanuel Ganotakis
@sl
prefLabel
Emmanuel Ganotakis
@ast
Emmanuel Ganotakis
@en
Emmanuel Ganotakis
@es
Emmanuel Ganotakis
@nl
Emmanuel Ganotakis
@sl
P106
P1153
7003650073
P21
P31
P496
0000-0001-8093-7562